Liya Ding, PhD | Meet a Scientist
Dr. Liya Ding, of Dana-Farber Cancer Institute, is a 2021 recipient of OCRA’s Liz Tilberis Early Career Award. With her project, “Targeting Therapeutic Resistance to PARP Inhibition in Ovarian Cancer,” … Continued
News
FDA Approves Drug to Identify Ovarian Cancer Lesions During Surgery
In what could prove to be a game-changer for ovarian cancer debulking procedures, the U.S. Food and Drug Administration (FDA) has approved Cytalux (pafolacianine), an imaging drug designed to help … Continued
Bojana Stefanovska, PhD | Meet a Scientist
Dr. Bojana Stefanovska, at University of Minnesota Twin Cities, is a 2021 recipient of OCRA’s Ann and Sol Schreiber Mentored Investigator Award. Her project, “APOBEC3B and DNA Repair as Synthetic … Continued
The Overview: November 2021
As we head into the Thanksgiving holiday, we have much to be thankful for … an embracing and strong survivor community, supporters who remain ever committed to the cause, and … Continued
OCRA-Funded Study Points to New Approach to Improve Ovarian Cancer Treatment
The following is a press release from University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, and Magee-Womens Research Institute PITTSBURGH, Nov. 12, 2021 – Immune checkpoint inhibitors are a … Continued
The Overview: October 2021
Have we got a roundup in store! You heard from us a lot in September (thanks to you, we surpassed our Ovarian Cancer Awareness Month fundraising goal!) and there’s still … Continued
Study Finds Germline Ovarian Cancer Mutations Occur Equally in Black and White Patients
A recent study has shed more light on the demographics of hereditary ovarian cancer, and provides further data to suggest an urgent need for increased genetic counseling for potentially high-risk … Continued
Finding the Story in the Data | Meet a Scientist
Sridevi Challa, PhD, an OCRA grantee at UT Southwestern, is on the receiving end of some major accolades. She is the lead author of a study that dozens of news … Continued
OCRA-Funded Study Identifies Role of Deubiquitinating Enzyme in Ovarian Cancer Progression
OCRA grantee Dr. Sumegha Mitra of Indiana University and colleagues have identified the mechanism by which a specific deubiquitinating enzyme known as UCHL1 promotes the growth of high-grade serous ovarian cancer in … Continued
Groundbreaking Initiative Seeks to Accelerate Development of New Treatments with OCRA’s Support
LOS ANGELES – (BUSINESS WIRE)–Global Coalition for Adaptive Research (GCAR) announces a new clinical trial initiative, Ovarian CanceRxTM. This innovative trial, referred to as an adaptive platform trial, is designed to … Continued
The Overview: August 2021
As we count down to Ovarian Cancer Awareness Month and our virtual National Conference, there are so many ways to get involved … whether by learning more and connecting with … Continued
OCRA-Funded Research Reveals New Ovarian Cancer Biomarker and Growth Mechanisms
Researchers at UT Southwestern have discovered a potential “Achilles’ heel” in ovarian cancer cells, and a new biomarker that may open up more avenues for targeted therapies. The study, published … Continued